Beglinger Christoph
Division of Gastroenterology, University Hospital, Basel, Switzerland.
Curr Opin Investig Drugs. 2002 Apr;3(4):587-8.
This review focuses on the satiating effect of cholecystokinin (CCK) in humans. Current evidence supports a role for the peptide as a physiological satiety factor. The therapeutic potential of CCK analogs cannot be estimated until further studies are performed that demonstrate the efficacy of analogs for decreasing body weight, and the safety of CCK when administered chronically. Because the brain-gut axis is so important in the normal control of food intake, a great deal of caution is needed, particularly with agents that will presumably be taken for prolonged periods. Even so, at present it seems likely that we will see the introduction of CCK analogs or CCK antagonists as a new class of appetite-modulating agents in the not-too-distant future.
本综述聚焦于胆囊收缩素（CCK）对人类的饱腹感作用。目前的证据支持该肽作为一种生理性饱腹感因子的作用。在进行进一步研究以证明CCK类似物减轻体重的功效以及长期给药时CCK的安全性之前，无法评估CCK类似物的治疗潜力。由于脑-肠轴在食物摄入的正常控制中非常重要，因此需要格外谨慎，尤其是对于可能需要长期服用的药物。即便如此，目前看来，在不久的将来我们很可能会看到CCK类似物或CCK拮抗剂作为一类新型食欲调节药物被引入。
